SCHEMBL5546060

SCHEMBL5546060

Cc1cocc1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.45
CYP2B6 P20813 1/20 0.45
ESR2 Q92731 2/20 0.42
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
ENPP3 O14638 1/20 0.40
ENPP1 P22413 1/20 0.40
ESR1 P03372 2/20 0.39
ALDH1A1 P00352 6/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
BACE1 P56817 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10615231 0.82 ESR1 (0.55) CYP2A6CYP2B6PDCD1CD274ESR1
SCHEMBL5545802 0.77 ESR1 (0.41) CYP2A6ESR2ESR1ALDH1A1HPGD
SCHEMBL28600946 0.77 ESR1 (0.37) ESR2ESR1
SCHEMBL28603589 0.76 ESR1 (0.32) ESR2ESR1
SCHEMBL5536957 0.76 MAOB (0.45) ALDH1A1HPGDTSHRNPC1RAB9A
SCHEMBL12270245 0.75 ESR1 (0.48) CYP2A6ESR2PDCD1CD274ESR1
SCHEMBL12205435 0.74 ESR1 (0.39) CYP2A6ESR2ESR1ALDH1A1NPC1
SCHEMBL28288265 0.74 ABL1 (0.44) ESR2ENPP3ALDH1A1NPC1RAB9A
SCHEMBL4830408 0.74 ESR2 (0.60) CYP2A6CYP2B6ESR2PDCD1CD274
SCHEMBL11434251 0.73 MAPT (0.46) ESR1ALDH1A1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980837-B2 Inhibitors of IAP GENENTECH, INC. (US) 2015-03-17 US disclosed
US-8980837-B2 Inhibitors of IAP GENENTECH, INC. (US) 2015-03-17 US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-20120202750-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2012-08-09 US disclosed
US-20120202750-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2012-08-09 US disclosed
US-8110568-B2 Inhibitors of IAP GENENTECH, INC. (US) 2012-02-07 US disclosed
US-20110077265-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-03-31 US disclosed
US-20110046066-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-02-24 US disclosed
US-20100256115-A1 INHIBITORS OF IAP COHEN FREDERICK 2010-10-07 US disclosed
WO-2009089502-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-16 WO disclosed
US-20070299052-A1 Inhibitors of IAP GENENTECH, INC. (US) 2007-12-27 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-7244851-B2 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2007-07-17 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP2A6 1119/4885CYP2B6 758/4885ESR2 339/4885
US-20070299052-A1 Inhibitors of IAP XIAP, BIRC5, BIRC3 CYP2A6 4773/4885CYP2B6 4840/4885ESR2 2293/4885
US-20110046066-A1 INHIBITORS OF IAP BIRC5, XIAP, BIRC3 CYP2A6 4767/4885CYP2B6 4806/4885ESR2 2173/4885
US-20120202750-A1 INHIBITORS OF IAP XIAP, BIRC5, BIRC3 CYP2A6 4773/4885CYP2B6 4840/4885ESR2 2293/4885
US-20100256115-A1 INHIBITORS OF IAP XIAP, BIRC5, BIRC3 CYP2A6 4773/4885CYP2B6 4840/4885ESR2 2293/4885
US-20110077265-A1 INHIBITORS OF IAP XIAP, BIRC5, BIRC2 CYP2A6 4661/4885CYP2B6 4750/4885ESR2 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.